Media stories about TrovaGene (NASDAQ:TROV) have trended somewhat positive on Tuesday, AlphaOne reports. The research group, a division of Accern, identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. AlphaOne ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. TrovaGene earned a media sentiment score of 0.11 on AlphaOne’s scale. AlphaOne also gave news articles about the medical research company an impact score of 88 out of 100, indicating that recent news coverage is very likely to have an effect on the company’s share price in the near term.
These are some of the news articles that may have impacted AlphaOne Sentiment Analysis’s analysis:
- Maxim Group Kept TrovaGene (NASDAQ:TROV) As a “Buy”; They … – WeeklyHub (weeklyhub.com)
- Key Researchers at Maxim Group Reiterate their ‘Buy’ rating for TrovaGene (NASDAQ:TROV) Shares Today. Their … – Weekly Register (weeklyregister.com)
- Trovagene Signs Deal With AstraZeneca (sdbj.com)
- TROVAGENE, INC. : Submission of Matters to a Vote of Security Holders (form 8-K) (4-traders.com)
TrovaGene (NASDAQ TROV) traded down 3.5817% on Tuesday, reaching $0.9072. 117,908 shares of the company traded hands. The stock’s 50 day moving average price is $0.82 and its 200 day moving average price is $1.54. TrovaGene has a one year low of $0.61 and a one year high of $5.98. The company’s market capitalization is $28.10 million.
A number of equities analysts recently weighed in on TROV shares. S&P Equity Research lifted their target price on shares of TrovaGene from $1.55 to $1.80 in a research note on Friday, March 10th. Zacks Investment Research downgraded shares of TrovaGene from a “buy” rating to a “hold” rating in a research note on Wednesday, March 15th. Piper Jaffray Companies downgraded shares of TrovaGene from a “neutral” rating to an “underweight” rating in a research note on Thursday, March 16th. Maxim Group downgraded shares of TrovaGene from a “buy” rating to a “hold” rating in a research note on Thursday, March 16th. Finally, Cantor Fitzgerald set a $8.00 price target on shares of TrovaGene and gave the company a “buy” rating in a research note on Saturday, March 18th.
ILLEGAL ACTIVITY WARNING: This piece was originally published by Stock Observer and is the property of of Stock Observer. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://www.thestockobserver.com/2017/06/20/trovagene-trov-getting-somewhat-favorable-press-coverage-study-finds-updated.html.
Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.
Receive News & Ratings for TrovaGene Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene Inc. and related companies with MarketBeat.com's FREE daily email newsletter.